Sugi Predict

Sugi Predict / Targets / RIPK3

RIPK3

Receptor-interacting serine/threonine-protein kinase 3 · Q9Y572 · RIPK3 on Sugi Atlas →

39,112 patent compounds predicted against RIPK3, 30,489 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL362582 SCHEMBL362582 0.47 4/20
SCHEMBL369946 SCHEMBL369946 0.58 3/20
SCHEMBL371540 SCHEMBL371540 0.56 3/20
Sorafenib Sorafenib (SCHEMBL8218) 1.00 2/20
Tivozanib Tivozanib (SCHEMBL172883) 1.00 2/20
Motesanib Motesanib (SCHEMBL187470) 1.00 2/20
SCHEMBL372070 SCHEMBL372070 0.85 2/20
Sorafenib Sorafenib (SCHEMBL162935) 0.81 2/20
Exelixis Exelixis (SCHEMBL371899) 0.81 2/20
SCHEMBL170976 SCHEMBL170976 0.80 2/20
Sorafenib Sorafenib (SCHEMBL19322) 0.80 2/20
SCHEMBL33143 SCHEMBL33143 0.79 2/20
SCHEMBL371644 SCHEMBL371644 0.77 2/20
SCHEMBL371732 SCHEMBL371732 0.77 2/20
SCHEMBL170966 SCHEMBL170966 0.74 2/20
SCHEMBL371775 SCHEMBL371775 0.73 2/20
SCHEMBL372083 SCHEMBL372083 0.73 2/20
SCHEMBL202067 SCHEMBL202067 0.72 2/20
SCHEMBL371806 SCHEMBL371806 0.72 2/20
SCHEMBL371980 SCHEMBL371980 0.72 2/20

Clinical trials — most relevant to RIPK3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer PHASE4UNKNOWN
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Clinical and Genomic Responses to Open Heart Surgery PHASE3COMPLETED
The G Protein-Coupled Receptor Kinase Type 2 Inhibitor Paroxetine as Adjunctive Therapy to Improve Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus PHASE3UNKNOWN
Ursodeoxycholic Acid as add-on Therapy in Type 2 Diabetes Mellitus PHASE2/PHASE3UNKNOWN
The Biology of Chronic Preconditioning: Genomic and Physiologic Mechanisms of Response PHASE2UNKNOWN
MIT-001 for Prevention of CCRT-Induced OM in HNSCC Patients PHASE2ACTIVE_NOT_RECRUITING
Efficacy and Safety of Drug Combination Therapy of Isotretinoin and Some Antifungal Drugs as A Potential Aerosol Therapy for COVID-19 : An Innovative Therapeutic Approach COVID-19 PHASE2UNKNOWN
Remote Ischaemic Conditioning in Endovascular Recanalization for Proximal Anterior Circulation Occlusion Study PHASE1UNKNOWN
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia EARLY_PHASE1COMPLETED
Limb RIPC in Patients Undergoing Lung Lobectomy. Study of Oxidative Lung Damage nanCOMPLETED
Glucagon Like Peptide-1 in Remote Ischemic Conditioning nanCOMPLETED
Molecular Mechanism of Neutrophil Necroptosis and Its Roles in RA Pathogenesis nanUNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932) nanRECRUITING
Remote Ischemic Preconditioning to Prevent Contrast-Induced Kidney Injury in Diabetic Patients (PRINCES) nanCOMPLETED
Apoptosis Markers in Aggressive Periodontitis nanCOMPLETED
Effect of Periodontal Treatment on Inflammasome Proteins in Periodontal Diseases nanUNKNOWN
New Signaling Pathway Targeting Systemic Lupus Erythematosus nanUNKNOWN
Remote Ischemic Preconditioning in Patients Undergoing Acute Minor Abdominal Surgery nanCOMPLETED
Autophagy in Systemic Lupus Erythematosus nanUNKNOWN
Autophagy Bladder Cancer nanUNKNOWN
Evaluation of Serum Gasdermin D Level As a Potential Biomarker of Disease Activity in Vitiligo Patients nanUNKNOWN
SMYD3-Driven Metabolic Rewiring in Colorectal Liver Metastases nanNOT_YET_RECRUITING
Impact of CASP3 Gene in Chemoresistance nanNOT_YET_RECRUITING
Abnormalities in the Effects of Insulin and Exercise on Glucose- and Lipid Metabolism in Obesity and Type 2 Diabetes nanCOMPLETED
Inflammasomes in Cell Death in FTMH, ERM, and RRD nanCOMPLETED
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus nanCOMPLETED
ADAR1 Expression Level in Rectal Cancer nanRECRUITING
Circulating Markers for Ischemic Heart Disease nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a RIPK3 binder may also engage these)

ProteinNameSimilarity
Q9QZL0 — 0.995 Q9QZL0 →
Q9Z2P5 — 0.992 Q9Z2P5 →
Q0P5I2 — 0.990 Q0P5I2 →
Q3ULB5 — 0.988 Q3ULB5 →
Q4QQS0 — 0.987 Q4QQS0 →
IRAK2 Interleukin-1 receptor-associated kinase-like 2 0.986 landscape →
Q9Z1J2 — 0.985 Q9Z1J2 →
Q9Z0E3 — 0.985 Q9Z0E3 →
Q8BLR5 — 0.985 Q8BLR5 →
Q68UT7 — 0.985 Q68UT7 →
F1M5M3 — 0.985 F1M5M3 →
Q5R810 — 0.985 Q5R810 →
O70405 — 0.985 O70405 →
USP19 Ubiquitin carboxyl-terminal hydrolase 19 0.984 landscape →
Q8BHW9 — 0.984 Q8BHW9 →
Q8CFA1 — 0.984 Q8CFA1 →
Q8K330 — 0.984 Q8K330 →
TESK2 Dual specificity testis-specific protein kinase 2 0.984 landscape →
Q6XUX1 — 0.984 Q6XUX1 →
Q8CFK6 — 0.984 Q8CFK6 →
Q8R2S1 — 0.984 Q8R2S1 →
Q9R0A5 — 0.983 Q9R0A5 →
Q96PD2 — 0.983 Q96PD2 →
Q2LGB3 — 0.983 Q2LGB3 →
Q62406 — 0.983 Q62406 →
Q8VDG6 — 0.983 Q8VDG6 →
Q9Y6S9 — 0.983 Q9Y6S9 →
Q66HE5 — 0.982 Q66HE5 →
Q5RA67 — 0.982 Q5RA67 →
Q3UJD6 — 0.982 Q3UJD6 →